The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: French Childhood Cancer Survivor Study
Official Title: Constitution d'Une Cohorte Nationale r茅trospective de Survivants d'un Cancer Solide de l'Enfant diagnostiqu茅 Avant 2000
Study ID: NCT01620372
Brief Summary: The FCCSS is a multicentric national large-scale collaborative population-based study of children treated for a solid tumor before 2000 in France and before the age of 19 years. The study is concerned by improving knowledge about the long-term effects caused by cancer and its treatments including adverse health and social outcomes. The main reason of the FCCSS is to estimate the risk of adverse health and social outcomes that may occur after a cancer treatment and to prevent them by providing adapted follow-up care. The cohort will be followed for up to 20 years from 2011.
Detailed Description: The main objectives of the FCCSS are to: * estimate the relationship between doses received (radiotherapy, chemotherapy) at a given organ and risk of second malignancy tumors; * help identify patients at higher risk; * compare the mortality occurred among the survivors with the general population; * investigate the consequences of various intensities of exposure to chemotherapy and/or radiation on health outcomes (such as cardiovascular, cerebrovascular and thyroid diseases, diabetes,...); * characterize survivors with respect to socioeconomic status and quality of life. The cohort will be ascertained using: * the medical records from the treatment centers in order to characterize the childhood cancer, estimate doses of radiotherapy received by all organs and measure the chemotherapy administered; * the French National Identification Registry and the French Death Registry in order to obtain the vital status and the causes of the deaths for the former patients * a self-questionnaire that covers the entire future of the survivors (e.g. social status, family network, fertile offspring, access to care, access to bank loans, occupation,...); * the French National Health Insurance Information System that contains data on all reimbursements for health expenditure including medicinal products as well as outpatient medical and nursing care, prescribed or performed by healthcare professionals. In an initial cohort, we have already studied the iatrogenic effects of the cancer treatments. We have estimated the doses of ionising radiations delivered by radiotherapy to the target volume and by organs at distance. We found an important role of the radiotherapy and chemotherapy in the risk of a second cancer: * the cancers occuring after childhood cancer are in excess compared to the general population, * we studied the relationship between the brain radiation dose and the cerebrovascular mortality, * there is a high risk of cardiac pathology after anthracyclines administration for a childhood cancer, * cancer treatments increase the risk of second malignant neoplasms in digestive organs after a very long latency period, * the risk of thyroid adenoma increased with the radiation dose received by the thyroid during childhood cancer treatment, and plateaued at high doses, * there is a high long-term mortality risk for all types of second malignant neoplasms whatever the treatment received.
Minimum Age:
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Centre Hospital-Universitaire H么pital Nord, Amiens, , France
Centre Hospitalier-Universitaire, Angers, , France
Centre Hospitalier R茅gional Universitaire H么pital Saint-Jacques, Besan莽on, , France
Groupe hospitalier Pellegrin, Bordeaux, , France
Centre Hospitalier Universaitaire H么pital C么te de Nacre, Caen, , France
Centre Hospitalier Universitaire H么pial H么tel Dieu, Clermont Ferrand, , France
Centre Hospitalier Universaitaire h么pital d'enfants, Dijon, , France
H么pital La Tronche, Grenoble, , France
Centre Oscar Lambret, Lille, , France
H么pital Jeanne De Flandre, Lille, , France
H么pital de la m猫re et de l'enfant, Limoges, , France
Institut d'H茅matologie et Oncologie P茅diatrique, Lyon, , France
Centre R茅gional de Lutte Contre le Cancer Centre L茅on B茅rard, Lyon, , France
H么pital d'Enfants de Margency (HEM) Croix Rouge Fran莽aise, Margency, , France
AP-HM H么pital de la Timone, Marseille, , France
H么pital Arnaud De Villeneuve, Montpellier, , France
Centre Hospitalier Universaitaire H么pital m猫re-enfant, Nantes, , France
Centre Antoine Lacassagne, Nice, , France
GCS H么pitaux p茅diatriques Centre Hospitalier Universitaire Lenval, Nice, , France
Institut Curie, Paris, , France
H么pital Armand Trousseau, Paris, , France
CHRU de Poitiers La Miletrie, Poitiers, , France
Institut Jean Godinot, Reims, , France
Centre Hospitalier Universitaire de Reims H么pital Maison Blanche, Reims, , France
Centre Hospitalier Universitaire H么pital Sud, Rennes, , France
H么pital Charles-Nicolle, Rouen, , France
Centre Hospitalier Universitaire H么pital Nord, Saint Etienne, , France
Centre Ren茅 Gauducheau de Nantes Atlantique, Saint-Herblain, , France
Centre Hospitalier de Saintonge, Saintes, , France
H么pital Hautepierre, Strasbourg, , France
Institut Claudius Regaud, Toulouse, , France
H么pital des Enfants, Toulouse, , France
H么pital Clocheville, Tours, , France
H么pital Brabois enfants CHU de Nancy, Vandoeuvre-les-Nancy, , France
Centre R茅gional de Lutte Contre le Cancer de Lorraine ALEXIS VAUTRIN, Vandoeuvre-les-Nancy, , France
Institut Gustave Roussy, Villejuif, , France
Name: Florent F. de Vathaire, Ph.D.
Affiliation: Institut National de la Sant茅 Et de la Recherche M茅dicale, France
Role: PRINCIPAL_INVESTIGATOR